Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 53 of 58, showing 10 Applications out of 576 total, starting on record 521, ending on 530

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

521.

ECCT/25/04/03   PRETERM AFRICA STUDY
    Pragmatic Evaluation of Therapies to Enhance Respiratory Management in Preterm Infants in Africa   
Principal Investigator(s)
1. Nayirat Mohamed
Site(s) in Kenya
1. Coast General Teaching and Referral Hospital (Mombasa county)
 
10-03-2026 View

522.

ECCT/25/04/04   LIMIT
    A Low INR to Minimize bleeding with mechanical valves Trial (LIMIT)   
Principal Investigator(s)
1. Anthony KIBUKA Gikonyo
Site(s) in Kenya
The Karen Hospital
 
12-11-2025 View

523.

ECCT/25/04/07   Server migration
    Server Migration   
Principal Investigator(s)
1. Server Migration Server Migration
Site(s) in Kenya
Server Migration
 
30-04-2025 View

524.

ECCT/25/05/01   Sparkle Study Site 1403
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive CrisesA phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
18-12-2025 View

525.

ECCT/25/05/02   Hibiscus 2 - Site 251
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. Site 251 - Ahero Clinical Trails Unit, CREATES Strathmore University (Kisumu county)
 
16-12-2025 View

526.

ECCT/25/05/03   Hibiscus 2 - Site 253
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Site 253 - International Cancer Institute (Uasin Gishu county)
 
25-11-2025 View

527.

ECCT/25/05/04   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Bernhard Ogutu
Site(s) in Kenya
1. KEMRI Kondele Children\'s Hospital (Kisumu county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. Gertrudes Childrens Hospital (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
6. KEMRI WALTER REED KERICHO (Kericho county)
7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
 
09-12-2025 View

528.

ECCT/25/05/05   Hibiscus 2 - Site 252
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county)
 
15-10-2025 View

529.

ECCT/25/05/06   Hibiscus 2 - Site 254
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county)
 
26-11-2025 View

530.

ECCT/25/05/07   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Jessie Githanga
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. KEMRI Kondele Children\'s Hospital (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
 
21-11-2025 View